| Novel strategies targeting bromodomain-containing protein 4 (BRD4) for cancer drug discovery D Liang, Y Yu, Z Ma European journal of medicinal chemistry 200, 112426, 2020 | 48 | 2020 |
| Specific non-genetic IAP-based protein erasers (SNIPERs) as a potential therapeutic strategy Z Ma, Y Ji, Y Yu, D Liang European journal of medicinal chemistry 216, 113247, 2021 | 31 | 2021 |
| Discovery and development of selective aldehyde dehydrogenase 1A1 (ALDH1A1) inhibitors B Li, K Yang, D Liang, C Jiang, Z Ma European journal of medicinal chemistry 209, 112940, 2021 | 20 | 2021 |
| Development of Novel Anticancer Agents with a Scaffold of Tetrahydropyrido[4,3-d]pyrimidine-2,4-dione Z Ma, G Gao, K Fang, H Sun ACS Medicinal Chemistry Letters 10 (2), 191-195, 2019 | 19 | 2019 |
| Novel hydrazone moiety-bearing aminopyrimidines as selective inhibitors of epidermal growth factor receptor T790M mutant M Qin, T Wang, B Xu, Z Ma, N Jiang, H Xie, P Gong, Y Zhao European Journal of Medicinal Chemistry 104, 115-126, 2015 | 17 | 2015 |
| Discovery of benzimidazole derivatives as potent and selective aldehyde dehydrogenase 1A1 (ALDH1A1) inhibitors with glucose consumption improving activity Z Ma, L Jiang, B Li, D Liang, Y Feng, L Liu, C Jiang Bioorganic & medicinal chemistry 46, 116352, 2021 | 11 | 2021 |
| Synthesis and Anti‐Hepatitis B Virus Evaluation of 7‐Methoxy‐3‐heterocyclic quinolin‐6‐ols Y Liu, G Feng, Z Ma, C Xu, Z Guo, P Gong, L Xu Archiv der Pharmazie 348 (11), 776-785, 2015 | 7 | 2015 |
| Bromodomain-containing protein 4 (BRD4): a key player in inflammatory bowel disease and potential to inspire epigenetic therapeutics Z Ma, AA Bolinger, J Zhou, B Tian Expert Opinion on Therapeutic Targets 27 (1), 1-7, 2023 | 6 | 2023 |
| Design, synthesis of 1, 3-dimethylpyrimidine-2, 4-diones as potent and selective aldehyde dehydrogenase 1A1 (ALDH1A1) inhibitors with glucose consumption improving activity Z Ma, L Jiang, G Li, D Liang, L Li, L Liu, C Jiang Bioorganic Chemistry 101, 103971, 2020 | 6 | 2020 |
| IDR-targeting compounds suppress HPV genome replication via disruption of phospho-BRD4 association with DNA damage response factors SY Wu, HT Lai, NS Banerjee, Z Ma, JF Santana, S Wei, X Liu, M Zhang, ... Molecular cell 84 (2), 202-220. e15, 2024 | 4 | 2024 |
| Drug discovery targeting nuclear receptor binding SET domain protein 2 (NSD2) Z Ma, AA Bolinger, H Chen, J Zhou Journal of medicinal chemistry 66 (16), 10991-11026, 2023 | 4 | 2023 |
| Synthesis of pyrido [4, 3–d] pyrimidine-2, 4 (1H, 3H)-diones and pyrido [4, 3–d] pyrimidine-2, 4, 5 (1H, 3H, 6H)-triones by oxidative aromatization Z Ma, G Gao, H Sun Tetrahedron Letters 67, 152847, 2021 | 3 | 2021 |
| RIPTACs: A groundbreaking approach to drug discovery Z Ma, AA Bolinger, J Zhou Drug Discovery Today, 103774, 2023 | 2 | 2023 |
| 174 BRD4 AS A POTENTIAL THERAPEUTIC TARGET FOR CROHN'S DISEASEASSOCIATED FIBROSIS C McAninch, M Chulkina, Z Ma, SB McAninch, RM Edwards, A Seideneck, ... Gastroenterology 166 (5), S-40, 2024 | | 2024 |
| DEVELOPMENT OF NANOPARTICLE-ENCAPSULATED BRD4 INHIBITORS FOR NOVEL EPIGENETIC THERAPEUTICS OF IBD M Shah, Z Ma, H Chen, Y Cong, J Zhou, E Rytting, B Tian Inflammatory Bowel Diseases 29 (Supplement_1), S4-S4, 2023 | | 2023 |
